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In searching the Staphylococcus aureus genome, we previously identified sarT, a homolog of sarA, which
encodes a repressor for -hemolysin synthesis. Adjacent but transcribed divergently to sarT is sarU, which
encodes a 247-residue polypeptide, almost twice the length of SarA. Sequence alignment disclosed that SarU,
like SarS, which is another SarA homolog, could be envisioned as a molecule with two halves, with each half
being homologous to SarA. SarU, as a member of the SarA family proteins, disclosed conservation of basic
residues within the helix-turn-helix motif and within the beta hairpin loop, two putative DNA binding domains
within this protein family. The transcription of sarU is increased in a sarT mutant. Gel shift and transcriptional
fusion studies revealed that SarT can bind to the sarU promoter region, probably acting as a repressor for sarU
transcription. The expression of RNAII and RNAIII of agr is decreased in a sarU mutant. As RNAIII expression
is up-regulated in a sarT mutant, we hypothesize that sarT may down regulate agr RNAIII expression by
repressing sarU, a positive activator of agr expression. We propose that, in addition to the quorum sensing
effect of the autoinducing peptide of agr, the sarT-sarU pathway may represent a secondary amplification loop
whereby the expression of agr (e.g., those found in vivo) might repress sarT, leading to increased expression of
sarU. Elevated sarU expression would result in additional amplification of the original agr signal.
Staphylococcus aureus is an important human pathogen in
both the community and hospital settings (33). The spectrum
of diseases caused by this organism is extremely broad, ranging
from cutaneous to deep-seated infections such as pneumonia,
endocarditis, and sepsis (33). Within its arsenal are virulence
genes coding for proteins that facilitate tissue colonization,
immune evasion, and tissue destruction (33). Superimposed
upon these virulence genes is a network of regulatory genes
that confer precise gene expression during different stages of
infection (2, 6, 33). Expression of the regulatory elements, in
turn, exerts transcriptional control of unlinked target genes.
During growth in vitro, S. aureus expresses a number of cell
wall-associated adhesins that are believed to promote host
tissue colonization. In transition to the postexponential phase,
the expression of cell wall proteins is repressed while the syn-
thesis of exoproteins predominates, presumably to facilitate
host cell lysis (33).
Postexponential protein expression in S. aureus is generally
governed, in part, by global regulatory elements such as agr
(20), sae (15), and sarA (10). The agr locus, a pleiotropic
regulator of exoprotein synthesis in S. aureus, comprises two
divergent transcripts, RNAII and RNAIII (20, 28, 29, 32),
which encode agrDBCA and hld, respectively. AgrC and AgrA
correspond to the sensor and activator of a two-component
regulatory system (20). AgrD encodes a 46-residue peptide
which, aided by AgrB, undergoes processing and cyclization to
yield a quorum-sensing cyclic peptide (17). AgrC is the puta-
tive sensor for this cyclic peptide (23) and, upon phosphoryla-
tion, will lead to a second phosphorylation step of the activator
AgrA. Phosphorylated AgrA is believed to bind to the agr
promoter to activate transcription of RNAIII, which, as the
regulatory molecule, up-modulates the transcription of exo-
protein genes and down-modulates the expression of cell wall
protein genes during the postexponential phase (32).
Contrary to agr, the sarA locus up-regulates the expression
of many cell wall proteins (e.g., fibronectin binding protein A)
and selected exoproteins (e.g.,  [hla] and  hemolysins) (10)
while repressing the transcription of the protein A gene (spa)
(9). The sarA locus comprises a major 372-bp sarA open read-
ing frame driven by three distinct promoters (4). DNA binding
studies revealed that SarA, the major sarA effector molecule,
binds to several target gene promoters (e.g., agr, hla, and spa)
to modulate gene transcription (12), thus accounting for both
agr-dependent and agr-independent pathways of regulation. As
mutations in sarA or agr have been found to affect the tran-
scription of over 100 genes (14), it is not surprising that other
regulatory factors may be at work, in part to control SarA and
agr expression and also to regulate genes downstream of the
sarA-agr regulatory cascade. We and others have found several
SarA homologs that are involved directly or indirectly in viru-
lence gene regulation. SarR, being a SarA homolog with a
molecular mass of 13.6 kDa (26), represses sarA (26), agr, hla,
hlb, and spa expression during the postexponential phase (un-
published data), presumably by binding to the sarA or other
target gene promoters. SarS (also called SarH1), a 250-residue
SarA homolog (11, 37) repressible by agr, likely acts down-
stream of agr to up-regulate spa expression. An additional
regulatory gene with partial homology to SarA, rot, is a repres-
sor of hla and probably acts downstream of agr (27).
In searching the recently released S. aureus genomes (www
.ncbi.nlm.nih.gov/genome/ and www.TIGR.org), we found ad-
ditional SarA homologs. One of these homologs, SarT (a 118-
residue protein), is a repressor of hla expression and is nega-
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tively controlled by sarA (36). Contiguous to sarT, but
transcribed in opposite orientation, is sarU. The expression of
sarU is negatively controlled by sarT. Phenotypic and transcrip-
tional analysis revealed that sarU is a positive regulator of
RNAIII and contributes to the expression of virulence genes
controlled by agr.
MATERIALS AND METHODS
Bacterial strains, plasmids, and growth media. The bacterial strains and
plasmids used in this study are listed in Table 1. CYGP, 0.3GL medium (30), and
tryptic soy broth were used for the growth of S. aureus strains, while Luria-
Bertani broth was used to cultivate Escherichia coli. Antibiotics were used at the
following concentrations: erythromycin at 5 g/ml, kanamycin at 50 g/ml, tet-
TABLE 1. Strains and plasmids used
Strain or plasmid Reference or source Comments
S. aureus
RN4220 31 Mutant of 8325-4 that accepts foreign DNA
RN6390 31 Laboratory strain that maintains its hemolytic pattern when propagated on sheep
erythrocyte agar (parental strain)
RN6911 20 agr mutant of RN6390 with an agr::tetM mutation
ALC1342 Laboratory strain A sarA mutant with deletion of open reading frame 3 and the sarA open reading
frame and replaced with an ermC gene
ALC1713 26 sarR mutant of RN6390 with sarR::ermC
ALC1905 36 sarT mutant of RN6390 with sarT::ermC
ALC2071 36 sarT mutant ALC1905 carrying pSK236 with wild-type sarT gene
ALC1927 11 sarS mutant of RN6390 with sarS::ermC
ALC2272 This study sarU mutant of RN6390 with a deletion of amino acids 1 to 153 of the N terminus of
the sarU gene product and its replacement with an ermC gene
ALC2380 This study RN6390 with pALC2360
ALC2381 This study ALC2272 with pALC2360
ALC2601 This study RN6390 with pALC2591
ALC2602 This study RN6390 with pALC2599
ALC2604 This study RN6911 with pALC2591
ALC2605 This study RN6911 with pALC2599
ALC2607 This study ALC1905 with pALC2591
ALC2608 This study ALC1905 with pALC2599
ALC2609 This study ALC2272 with pALC2591
ALC2610 This study ALC2272 with pALC2599
ALC2714 This study RN6390 with pALC2707
ALC2716 This study ALC1905 with pALC2707
ALC2717 This study ALC2272 with pALC2707
E. coli
XL-1 Blue 25 Host strain for cloning
Topo InvF Invitrogen Host strain for the TA cloning vector
BL21(DE3)pLysS Novagen Host strain for the pET expression system
Plasmids
pCL52.2 34 Temperature-sensitive E. coli-S. aureus shuttle vector
pCR2.1 Invitrogen E. coli cloning vector for direct cloning of PCR products
pET14b Novagen Expression vector in E. coli
pSK236 19 Shuttle vector containing pUC19 cloned into the HindIII site of pC194
pUC19 25 E. coli cloning vector
pALC1484 18 Modified pSK236 shuttle vector with a promoterless gfpuvr reporter gene preceded by
an S. aureus ribosome binding site
pALC1740 This study pALC1484 with the hla promoter
pALC1742 36 pALC1484 with the agr P2 promoter
pALC1743 18 pALC1484 with the agr P3 promoter
pALC1904 This study pET14b containing the 345-bp sarT gene at the XhoI/BamHI sites
pALC2208 This study pCR2.1 containing a 2.3-kb PCR sarU-sarT fragment with flanking upstream and
downstream sequences
pALC2229 This study pUC19 containing a 2.3-kb EcoRV-KpnI fragment from pALC2208 at the HincII and
KpnI sites
pALC2240 This study pCL52.2 containing a 2.9-kb DNA fragment, which has a deletion of a 547-bp ClaI-
HincII fragment that includes residue 1 to 153 of the N terminus of the sarU gene
product and an insertion of the 1.2-kb ermC gene at the EcoRI site
pALC2360 This study pSK236 with a 1.5-kb DNA fragment containing the sarU gene with a 392-bp upstream
sequence at the EcoRI site
pALC2591 This study pALC1484 with a 310-bp promoter fragment of the sarU gene fused with the gfpuvr
reporter gene at the EcoRI and XbaI sites
pALC2599 This study pALC1484 with a 147-bp promoter fragment of the sarU gene fused with the gfpuvr
reporter gene at the EcoRI and XbaI sites
pALC2707 This study pALC1484 with a 310-bp promoter fragment of sarT fused with the gfpuvr reporter
gene at the EcoRI site
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racycline at 5 g/ml, and chloramphenicol at 10 g/ml for S. aureus; and ampi-
cillin at 50 g/ml, chloramphenicol at 30 g/ml, and spectinomycin at 75 g/ml
for E. coli.
Genetic manipulations in E. coli and S. aureus. Based on homology with SarA,
the sarU gene product was identified in the S. aureus genome database (www.TI-
GR.org/). To construct a sarU mutant, the sarU gene together with flanking
sequences on both sides was amplified by PCR with the primers 5-TGACGAT
TTCGGCTGAACTTC-3 and 5-TGGAACACGAAATGGTGAAC-3, with
chromosomal DNA from strain RN6390 being used as the template. The 2.3-kb
PCR fragment was cloned into cloning vector pCR2.1 (Invitrogen, San Diego,
Calif.) in E. coli. The KpnI-EcoRV DNA fragment containing the 2.3-kb frag-
ment was then cloned into the KpnI and HincII sites of pUC19. A 547-bp
fragment comprising the N-terminal 153 amino acids of SarU was deleted by
restricting with HincII and ClaI and then replaced with an 1.2-kb ermC frag-
ment. The fragment containing an ermC insertion into the partially deleted sarU
gene was cloned into the temperature-sensitive shuttle vector pCL52.2 (22). The
recombinant pCL52.2 was transformed into RN4220 by electroporation (35).
Plasmid isolated from RN4220 was restriction digested for authenticity and
introduced into RN6390 by electroporation. Transformants were selected at
30°C on erythromycin- and tetracycline-containing agar plates. S. aureus
RN6390, harboring the recombinant pCL52.2 construct, was grown overnight at
30°C in liquid medium in the presence of erythromycin, diluted 1:1,000 in fresh
medium, and propagated at 42°C, a nonpermissive temperature for the replica-
tion of pCL52.2. This cycle was repeated four times, and the cells were plated
onto 03GL plates containing erythromycin and erythromycin-tetracycline to se-
lect for tetracycline-sensitive but erythromycin-resistant colonies, representing
mutants with double crossovers (a frequency of 102 after the fourth passage).
The mutations were confirmed by PCR and Southern hybridization with sarU
and ermC probes as described previously (25). One clone, designated ALC2272,
was selected for further study.
To complement the sarU mutation, a 1.5-kb fragment encompassing the sarU
gene and a 392-bp sequence upstream of the sarU transcription start site (see
below) was cloned into shuttle plasmid pSK236. The recombinant plasmid was
electroporated into RN4220, selecting for chloramphenicol-resistant colonies.
The transformant was verified by plasmid restriction analysis. The plasmid from
RN4220 was then electroporated into parental strain RN6390 and the sarU
mutant (ALC2272).
Immunoblot analysis. To assess SarA expression in different S. aureus strains,
cellular proteins were extracted from RN6390, the sarU mutant (ALC2272), and
the complemented strains (ALC2380 and ALC2381). In brief, after being pel-
leted, the cells were suspended in 1 ml of TEG buffer (25 mM Tris-Cl, 5 mM
EGTA; pH 8) and cell extracts were prepared from lysostaphin-treated cells as
described previously (13). Cell extracts were immunoblotted onto nitrocellulose
membranes. For the detection of SarA, monoclonal antibody 1D1 (1:6,000 dilu-
tion) was added to the blot and incubated for 3 h, followed by another hour of
incubation with a 1:10,000 dilution of goat anti-mouse alkaline phosphatase
conjugate (Jackson Immuno Research, West Grove, Pa.). Reactive bands were
detected with developing substrates as described previously (5).
Isolation of RNA and Northern blot hybridization. Overnight cultures of S.
aureus were diluted 1:50 in CYGP or tryptic soy broth and grown to mid-log
(optical density at 650 nm [OD650] 	 0.7), late log (OD650	1.1), and early
postexponential (OD650	1.7) phases. The cells were pelleted and processed with
a Trizol isolation kit (Gibco BRL, Gaithersburg, Md.) in combination with
0.1-mm-diameter sirconia-silica beads in a Biospec reciprocating shaker, as de-
scribed previously (8). Ten or 15 g of each sample was electrophoresed through
a 1.5% agarose–0.66 M formaldehyde gel in morpholinepropanesulfonic acid
(MOPS) running buffer (20 mM MOPS, 10 mM sodium acetate, 2 mM EDTA,
pH 7.0). Blotting of RNA onto Hybond N membranes (Amersham, Arlington
Heights, Ill.) was performed with a Turbo blotter alkaline transfer system
(Schleicher & Schuell, Keene, N.H.). For detection of specific transcripts (agr,
sarA, sarU, sarT, spa, coa, agr, and hla), gel-purified DNA probes were radiola-
beled with [-32P]dCTP with a random-primed DNA labeling kit (Roche Diag-
nostics GmbH) and hybridized under aqueous-phase conditions at 65°C (7). The
blots were subsequently washed, autoradiographed, and developed with Kodak
BioMax film or Kodak Blue film.
Primer extension analysis. Mapping of the 5 end of the sarU transcript was
performed with the primer 5-GTTGCTTTAACTCTTGAGTGAG-3, which is
complementary to the coding strand for sarU and is located at nucleotide posi-
tions 85 to 64 downstream from the putative initiation codon GTG. Primer
extension was carried out as described previously (3, 4).
Transcriptional fusion studies of RNAII, RNAIII, hla, and sarU and sarT
promoters linked to the gfpuvr reporter gene. A 229-bp fragment in forward (nt
1528 to 1756) and reverse (nt 1756 to 1528) positions (20), representing RNAII
and RNAIII promoter fragments, respectively, was amplified by PCR with
genomic DNA of S. aureus strain RN6390 as the template and cloned into the
TA cloning vector pCR2.1. Similarly, a 440-bp hla promoter fragment, repre-
senting sequence upstream of the ribosomal binding sites of hla, was cloned into
pCR2.1. Various lengths of the sarU promoter region (310 and 148 bp) extending
from the sequence upstream of the ribosomal binding sites were amplified by
PCR by using chromosomal DNA of S. aureus strain RN6390 and primers with
flanking EcoRI or XbaI sites. EcoRI and XbaI fragments containing RNAII,
RNAIII, hla, or various lengths of sarU promoter fragments were cloned into
shuttle plasmid pALC1484 (18), generating transcriptional fusions to the gfpuvr
reporter gene as pALC1743, pALC1742, pALC1740, pALC2591, and
pALC2599. As sarT is transcribed contiguously but divergently from sarU, we
also cloned the 310-bp sarU promoter fragment in reverse orientation to the
gfpuvr gene to yield a sarT promoter fragment driving the reporter gene
(pALC2707). The construction of plasmid pALC1484 and modification of gfpuv
(Clontech, Palo Alto, Calif.) to gfpuvr with a S65T mutation to yield a red shift
(excitation maxima from 395 to 488 nm) were described earlier (18). The orien-
tation and authenticity of the promoter fragments were confirmed by restriction
analysis and DNA sequencing. The recombinant plasmids containing the respec-
tive RNAIII, RNAII, and hla and sarU promoters driving the gfpuvr reporter
were first introduced into S. aureus strain RN4220 by electroporation (35).
Plasmids containing RNAII, RNAIII, and hla promoters were electroporated
into RN6390 and its isogenic sarU and sarT mutants, while the sarU and sarT
promoter constructs were introduced into RN6390, the isogenic agr, sarT, or sarU
mutant.
After overnight culture, S. aureus strains harboring the recombinant plasmids
were diluted 1:100 and grown at 37°C with shaking in tryptic soy broth containing
chloramphenicol (10 g/ml). Aliquots (100 l) were transferred hourly to mi-
crotiter plates to assay for cell density (OD650) and fluorescence for 10 h in a
FL600 fluorescence reader (BioTek Instrument, Winooski, Vt.). Promoter acti-
vation was plotted as mean fluorescence per OD unit over time, using the
average values from triplicate readings.
Overexpression and purification of SarT in a pET vector. The 420-bp DNA
fragment containing the full-length sarT gene was amplified by PCR by using
chromosomal DNA from S. aureus RN6390 as the template and primers con-
taining flanking restriction sites (XhoI and BamHI for sarT) to facilitate cloning
into the expression vector. The purified PCR product was digested with XhoI and
BamHI, gel purified, ligated into the expression vector pET14b (Novagen, Mad-
ison, Wis.), and transformed into E. coli XL-1 Blue. The recombinant plasmid
containing a full-length sarT coding region was confirmed by restriction digestion
and DNA sequencing. The recombinant plasmids were then transformed to E.
coli BL21(DE3) pLys.S. The resulting plasmid (pALC1904; see Table 1) con-
tained the entire sarT coding region in frame with an N-terminal His tag. The
expression of recombinant protein was induced by adding isopropyl-1-thio--D-
galactopyranoside (ITPG; final concentration, 1 mM) to a growing culture (37°C)
at an OD600 of 0.5. After a 4-h induction, the cells were harvested, resuspended
in binding buffer (5 mM imidazole, 0.5 M NaCl, 20 mM Tris-HCl, pH 7.9), frozen
by dipping in liquid N2, and thawed overnight in ice. Cellular debris were
removed by centrifugation (TL-100 tabletop ultracentrifuge; Beckman, Palo
Alto, Calif.) at 45,000 rpm for 60 min, and the clarified supernatant was applied
to a nickel affinity column (Novagen) in accordance with the manufacturer’s
instruction. The protein was eluted with the elution buffer (1 M imidazole, 0.5 M
NaCl, 20 mM Tris-HCl, pH 7.9), followed by dialysis in a buffer containing 20
mM Tris-Cl (pH 8.0), 50 mM NaCl, 1 mM EDTA, 10% glycerol, and 1 mM DTT.
The authenticity of the purified SarT protein was confirmed by N-terminal
sequencing, and the size and purity of the recombinant protein was verified by
sodium dodecyl sulfate gels stained with Coomassie brilliant blue R-250.
Gel shift assays. To determine whether the recombinant SarT protein binds to
the sarU promoter, a 150-bp fragment representing nucleotide positions 13 to
160 bp upstream of the sarU start codon was end labeled with [
-32P]ATP by
using the T4 polynucleotide kinase. Labeled fragment (0.1 ng) was incubated at
room temperature for 20 min with various amounts of purified SarT protein in
25 l of binding buffer (25 mM Tris-Cl, pH 7.5, 0.1 mM EDTA, 75 mM NaCl, 1
mM dithiothreitol, and 10% glycerol) containing 0.5 g of calf thymus DNA. The
reaction mixtures were analyzed in an 8.0% nondenaturing polyacrylamide gel.
The band shifts were detected by exposing dried gels to X-ray film.
RESULTS
Identification of the sarU gene. In searching for SarA ho-
mologs in the S. aureus N315 genome (www.ncbi.nlm.nih.gov
/genome/staphylococcus), we found at least 12 proteins homol-
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ogous to SarA (protein GI 13700508) with a default setting of
30 as the cutoff in the BLAST search (21). Some of these
homologs, including SarR (protein GI 13702095, with an e
value of 9e12), SarS (also called SarH1; protein GI 13700028,
with an e value of 1e16), SarT (also called SarH3; protein GI
13702448, with an e value of 9e17), and Rot (protein GI
13701558, with an e value of 0.003 and a 50% homology) (27)
have been previously studied. The remaining homologs, many
of which we are characterizing, are SarX (protein GI 13700559,
with an e value of 1e04 and a 46% homology), SarV (protein
GI 13702067, with an e value of 5e04 and a 48% homology),
SarZ (protein GI 13702335, with an e value of 0.002 and a 53%
homology), and three proteins of unknown function (proteins
GI 13701144, GI 13700062, and GI 13702441, with e values of
0.003, 0.030, and 0.066 and homologies of 48, 48, and 45%,
respectively). SarR is a 113-residue protein that binds to the
sarA promoter to down-modulate SarA protein expression
(26). SarS, a 250-residue protein whose expression is normally
repressed by sarA and agr (11, 37), acts as an activator of
protein A synthesis. SarT, identified initially by its homology to
SarA, is a 118-residue protein that functions as a repressor for
hla transcription (36). Adjacent to sarT but transcribed in the
opposite direction is a gene, designated sarU, that encodes
another SarA homolog (protein GI 13702449 with an e value of
2e15). SarU is the third protein that came up in our BLAST
search for SarA homologs, with SarT, SarS, and SarR being the
first, second, and fourth hits, respectively. SarU, a 247-residue
polypeptide (29,276 Da), is almost twice the size of the smaller
SarA homologs (e.g., SarA, SarR, and SarT). Similar to SarS,
SarU, which has a 64% homology to SarA, can be considered
to be a molecule with two halves (namely, SarU1, consisting of
residues 1 to 124, and SarU2, consisting of residues 125 to
247), with each half sharing sequence similarity to the smaller
SarA homologs (Fig. 1). SarU1 has a 25% sequence identity to
SarU2 and shares 56, 59, and 51% homology to SarA, SarT,
and SarR, respectively. Likewise, SarU2 has 56, 53, and 57%
homology to these respective proteins. Interestingly, when
SarU was analyzed with BLAST against the entire microbial
data bank, most of the hits with significant e values (e36 to
0.05) were proteins from S. aureus strains as well as from
Staphylococcus epidermidis. Only the MarR protein from Ba-
cillus subtilis yielded a significant e value of 0.045 (see Discus-
sion, below).
Translational and transcriptional start site and promoter
structure of sarU. To verify that the start codon of the sarU
gene is indeed GTG, a valine (V) residue, we resequenced our
cloned sarU fragment (pALC2208) by using primer 5-GTTG
CTTTAACTCTTGAGTGAG-3 (nucleotide positions 85 to
FIG. 1. Sequence alignment of SarU, SarA, SarR, SarT, and SarS. SarU is a 247-residue polypeptide. Based on regional homology, SarU can
be divided into two domains, U1 and U2, of 124 and 123 residues, respectively. The homology of SarU with a two-domain protein like SarS is
higher, with 39% identity and 64% homology. The conserved residues, seen in the black boxes, are designed as the majority at each position when
at least half of the residues have the same amino acid. The alignment was done by the Clustal program of DNASTAR.
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64 downstream from the putative start codon GTG). Repeated
sequencing confirmed GTG to be the start codon, with a strong
ribosome-binding site AGGAGA that is located 7 bp up-
stream. To determine the transcriptional start site and the
promoter sequences, primer extension was performed with an
identical primer, and total RNA was isolated from the wild-
type strain RN6390 and the isogenic sarT mutant (data not
shown). The transcriptional start site of sarU was mapped,
based on data from both strains, to an A residue located 90 bp
upstream of the initiation codon. Based upon the transcrip-
tional start site, the predicted promoter boxes are TATAAA
(10)–N16-TTTATA (35), which has close resemblance to
the 10 and 35 consensus sequences of A-dependent pro-
moters (16). The organization of the sarU-sarT intergenic re-
gion is complex, as the two genes are divergently transcribed
and separated by 323 bp, and the 10 region of the sarU and
sarT genes are located 97 and 233 bp upstream of their corre-
sponding start sites, respectively. The putative TATAAT
(10)–N24-AAGACA (35) promoter region for sarT is pred-
icated upon transcript size, and sequence prediction and pre-
cise mapping have not been done (36).
Expression of sarU in RN6390 and its isogenic agr, sarA,
sarR, sarS, and sarT mutants. To assess the role of sarU within
the sarA-agr regulatory cascade, we constructed a sarU mutant
by allelic replacement, essentially replacing the sarU gene with
an ermC cassette (see Materials and Methods). A 547-bp re-
gion, containing the N-terminal 153 amino acids of SarU and
an 88-bp sequence upstream of the translation start, was de-
leted and replaced with an 1.2-kb ermC fragment. PCR am-
plification with primers outside the ermC insertion yielded a
fragment that was 1.2 kb larger than the wild type, consistent
with an ermC insertion into the sarU gene. This result also
corroborated Southern hybridization data with selected ermC
and sarU probes (data not shown).
A Northern blot with a sarU probe (820 bp) that encom-
passed the coding region disclosed that the sarU gene was
poorly transcribed in the parental strain. Interestingly, the sarU
transcript, consisting of 1,200 nt, was enhanced in the sarT
mutant but not in the sarA, sarR, sarS, or agr mutants (Fig. 2).
Interestingly, the level of the sarU transcript was higher during
the postexponential phase (OD, 1.7) than in the exponential
phase (OD, 0.7). The size of the transcript (650 nm) also
hinted at the possible monocistronic nature of the sarU tran-
script. In addition to the 1,200-nt transcript, we also observed
an 1,400-nt transcript that hybridized with the sarU probe in
the sarT mutant. However, upon introducing the comple-
mented plasmid into the sarU mutant or the parental strain, we
were not able to restore the larger transcript (strains ALC2381
and ALC2380) in repeated attempts. A representative blot is
shown in Fig. 2A. This finding suggests that the larger tran-
script might arise from neighboring genes or a cross-hybridiz-
ing band (see Discussion, below). Nevertheless, the possibility
of a cryptic promoter in this region cannot be entirely ruled
out. Both transcripts were abolished in the complemented sarT
mutant (ALC2071 in Fig. 2B). The sarU transcript was unde-
tectable by Northern blotting in strain SH1000, an rsbU
strain, as well as in RN6390 (data not shown).
Gel shift assays of the SarT protein with sarU promoter
fragments. Since the transcription of sarU, a gene adjacent to
but divergently transcribed from sarT, is increased in a sarT
mutant (Fig. 2) but not vice versa (data not shown), we spec-
ulated that SarT might bind to the sarU promoter to modulate
sarU expression. Taking advantage of the fact that the coding
regions of sarU and sarT are only 323 bp apart, we amplified by
PCR a 148-bp sarU promoter fragment directly upstream of
the sarU ribosomal binding site. The fragment was end labeled
with [
-32P]ATP and used in gel shift assays with increasing
concentrations of purified SarT protein (Fig. 3). Retarded pro-
tein-DNA complexes can be detected with as little as 0.2 g of
protein (6.8 pM). As the concentrations of SarT increased,
multiple retarded DNA-protein complexes were discerned,
suggesting that multiple proteins may bind to the sarU pro-
moter region. Alternatively, SarT may bind to multiple sites on
the sarU promoter region. Based on the data, we estimated the
dissociation constant (Kd) to be 102.5 pM.
sarU and sarT promoter-gfpuvr fusion studies in isogenic
sarT and sarU strains. To confirm the involvement of sarT in
sarU expression, we constructed transcriptional fusions of two
sarU promoter fragments, representing 148 and 310 bp up-
stream of the sarU ribosomal binding site, to the gfpuvr reporter
gene. The constructs, pALC2591 and pALC2599, containing
310- and 148-bp fragments, respectively, were introduced into
the wild-type strain RN6390, the sarT mutant (ALC1905), the
agr mutant RN6911, and the sarU mutant (ALC2272) and
FIG. 2. (A) Northern analysis of the sarU transcript in sarA, agr,
sarT, sarR, and sarS mutants and in complemented strains at exponen-
tial (OD650, 0.7) (upper panel) and postexponential (OD650, 1.7)
(lower panel) phases of growth. Expression of the sarU transcript
appeared to be higher during the postexponential phase than during
the exponential phase in the sarT mutant, a conclusion drawn from
multiple repeated experiments. A total 15 g of cellular RNA was
loaded onto each lane. The blot was probed with an 820-bp sarU probe
containing the entire open reading frame of the sarU gene. The thin
arrow points to the 1,200-nt sarU transcript and the thick arrow
points to a 1,400-nt transcript (see Discussion). (B) Northern hybrid-
ization with the same fragment to the wild-type RN6390, sarT mutant
(ALC1905), and to ALC1905 complemented with a wild copy of the
sarT gene (ALC2071) and complemented sarU mutant (ALC2381).
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assayed for green fluorescence emitted from GFPuvr. The re-
sults, presented in Fig. 4B, disclosed that there are 7- to
11-fold increases in mean fluorescences attributable to sarU
promoter activity in the sarT mutant (1,007  95 and 657  65
fluorescence units plus or minus the indicated standard devi-
ations for pALC2599 and pALC2591, respectively) compared
to those in the parental strain (89  20 and 95  25 units for
pALC2599 and pALC2591, respectively). The levels of sarU
promoter activity in the sarU mutant (140  30 and 124  50
units for pALC2599 and pALC2591, respectively) were not
significantly higher than those in the parental strain, consistent
with a lack of significant autoregulatory effect. Although the
mean fluorescence values in the parental strain are not very
high, the level of sarU promoter activity in an isogenic agr
mutant (58  20 and 38  25 units versus 89  20 and 95  25
in the parental strain for pALC2599 and pALC2591, respec-
tively) was even lower. These results were consistent in several
repeated experiments. Collectively, these data confirmed the
role of sarT in repressing sarU expression and probably in
slightly lowering sarU promoter activity in the agr mutant rel-
ative to the parental strain.
We also attempted to verify whether sarT regulates its own
expression. For this experiment, we introduced pALC2707, a
gfpuvr construct carrying a 310-bp sarU promoter fragment with
an orientation opposite to that found in pALC2591, thus yield-
ing a sarT promoter-gfpuvr construct, into various strains and
then subjected them to fluorescence spectrometry. There were
only slight differences in GFP expression among the wild-type
FIG. 3. Autoradiogram of an 8.0% nondenaturing polyacrylamide
gel showing a gel shift assay for purified SarT protein with a sarU
promoter fragment. Purified SarT protein was allowed to bind a 148-bp
radiolabeled sarU promoter fragment. Lanes 1 to 9, mobility of the
148-bp DNA fragment with 0, 0.2, 0.3, 0.5, 0.75, 1.0, 2.0, 2.5, and 3.0 g
of purified SarT protein, respectively; lanes 10 and 11, mobility of the
same fragment in the presence of 1.0 g of the purified protein and a
40-fold excess (molar ratio) of unlabeled 148-bp sarU fragment and a
273-bp nonspecific DNA fragment, respectively.
FIG. 4. Promoter activation of the sarU promoter fused to a gfpuvr reporter gene, as evaluated with a fluorescence spectrophotometer (FL600;
BioTek Instruments). (A) Graphical representation of the 310- and 147-bp DNA fragments of sarU promoter region fused to a promoterless gfpuvr
gene with an S. aureus ribosome-binding site. The transcriptional start site, labeled as 1, was identified by primer extension, and the putative
promoter 10 and 35 boxed sequences are also indicated. The numbers at the lines (both top and bottom) are marked according to the
transcriptional start site and to the start codon of the sarU gene, respectively. (B) Recombinant shuttle constructs pALC2591, pALC2599, and
pALCALC2707 containing 310-bp, 148-bp, and reversed-orientation 310-bp sarU promoter fragments, respectively, were introduced into the wild
type and its isogenic mutant strains, namely, wild-type RN6390 (lanes 1), agr mutant RN6911 (lanes 2), sarT mutant ALC1905 (lanes 3), and sarU
mutant ALC2272 (lanes 4). To minimize variations in fluorescence attributable to cell density, the data are presented as the averages of reported
fluorescence per OD650 unit in triplicate samples obtained during the postexponential phase, when sarU promoter activity is expected to be higher (see
Fig. 2). The experiment was repeated several times, and one of the typical experiments is shown. A negative control with the shuttle vector pALC1484
alone lacking any promoter fragment was performed and showed no significant background (less than 50 mean fluorescence units) (data not shown).
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RN6390 (190  30 units), sarU mutant ALC2272 (236  50
units), and sarT mutant ALC1905 (243  45 units), thus con-
firming an absence of a major autoregulatory effect by sarT. In
addition, sarT regulates sarU but not vice versa.
GFP fusion assays for RNAII, RNAIII, and hla promoters in
a sarU mutant. In addition to the regulation of sarU by sarT, we
also found that sarU plays a regulatory role in target gene
expression. In previous studies, we have found that sarT can
repress the expression of RNAII and RNAIII (36). Cognizant
of the SarT-mediated repression of sarU (delineated above),
we hypothesized that sarT may repress RNAII and RNAIII
promoter activities by down-regulating sarU. If this hypothesis
were correct, one would expect RNAII and RNAIII expression
to be decreased in a sarU mutant. To verify this possibility, we
introduced plasmids containing an RNAII (pALC1742) or
RNAIII (pALC1743) promoter linked to gfpuvr into wild-type
RN6390 and the isogenic sarU mutant (ALC2272). Upon mon-
itoring bacterial growth and serial GFP expression over a 10-h
period, we found that the growth rates were comparable be-
tween these two constructs, with early stationary phase appear-
ing after 6 h of growth. However, the expression of RNAII
and RNAIII was significantly lower in the sarU mutant than in
the parental strain (Fig. 5A and B). Recognizing that RNAIII
activates hla transcription, we also explored the effect of the
sarU mutation on hla promoter activity (Fig. 5C). In parallel
with the RNAII and RNAIII data, the GFP-mediated fluores-
cence attributable to the hla promoter activity was lower in the
sarU mutant than in the parental strain. Northern blotting with
respective probes also confirmed the reduction in RNAII,
RNAIII, and hla expression in the sarU mutant relative to that
of the wild-type strain (data not shown).
Expression of sarA, spa, and coa (coagulase) in the sarU
mutant. The above data indicated that sarU positively regu-
lates agr RNAII and RNAIII expression. To determine
whether sarU also controls sarA, we assayed for sarA tran-
scripts (sarA P2, sarA P3, and sarA P1 transcripts originating
from P2, P3, and P1 promoters of the sarA locus, respectively)
in the sarU mutant. Our data indicated that sarA P2 and sarA
P1 transcripts expressed during the log phase were not signif-
icantly altered in the sarU mutant compared with the parental
strain (Fig. 6A). However, the sarA P3 transcript appeared to
be slightly increased in the sarU mutant during the early sta-
tionary phase, whereas sarA P1 and P3 transcripts were in-
creased and decreased, respectively, in the wild type carrying
sarU in a shuttle plasmid (ALC2380), and both sarA P1 and P3
transcripts were enhanced in the complemented mutant strain
(ALC2381). As differential activation of the three sarA pro-
moters leads to varying SarA protein levels, we also deter-
mined the overall sarU mutation effect on the expression of
SarA, the regulatory molecule of the sarA locus. Cell extracts
from parental, mutant, and complemented strains during the
stationary phase were obtained, and various amounts of ex-
tracts (5, 10, and 20 g) were analyzed by Western blotting
with anti-SarA monoclonal antibody 1D1. Significant alter-
ations in SarA expression were not observed among the wild
type (RN6390), sarU mutant (ALC2272), and complemented
strains (ALC2380 and ALC2381). These data suggest that,
despite the mild effect of sarU on individual sarA promoters,
sarU does not have a significant effect on the expression of
SarA.
The effect of the sarU mutation on the expression of protein
A was more variable, with a slight decrease in spa transcription
FIG. 5. GFP expression was driven by agr RNAII (A), agr RNAIII (B), and hla (C) promoters in the wild type (Wt) and in an isogenic sarU
strain of S. aureus. Bar diagrams represent various time points of the growth phase after inoculation. Samples obtained at 6 h of growth represent
early postexponential phase, a time point at which RNAII, RNAIII and hla promoter activities can easily be detected.
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in the mutant (Fig. 6B), thus indicating that sarU, besides its
effect on agr, may have a direct effect on the target gene as well.
One effect of agr is the repression of cell wall-associated pro-
tein genes, such as that for coagulase. To ascertain the effect of
sarU on coa, Northern blot analyses were conducted, revealing
that the coa transcript level was higher in the sarU mutant than
in the parental strain (Fig. 6C). As a control, we confirmed that
coa expression was higher in the agr mutant than in the paren-
tal strain. Upon providing the sarU in trans in the parental
strain (ALC2380), the transcript remained low. Curiously,
complementation of the sarU mutant in trans (ALC2381) did
not lead to a reduction in coa transcription as anticipated.
Conceivably, this may be due to a higher gene dosage or to
possible action of SarU in conjunction with other factor(s) that
cannot be readily restored with the sarU fragment.
DISCUSSION
In prior studies, we have observed that SarT, a SarA ho-
molog, represses hla expression in part by down-modulating
agr RNAIII expression (36). In deciphering the S. aureus ge-
nomes (www.TIGR.org and www.ncbi.nlm.nih.gov), we found
a divergently transcribed gene, sarU, adjacent to sarT. Remark-
ably, the transcription of sarU, not readily detected in the
parental strain, was enhanced in a sarT mutant but not vice
versa, indicating that sarT may repress sarU transcription. The
gene product of sarU is 247 residues in length, with a molecular
mass of 29,276 Da. As with many of the SarA homologs, SarU
is a basic protein with a pI of 9.81. Similar to SarS (sarH1),
which is a 250-residue SarA homolog, SarU can be envisioned
as a molecule with two halves, with each half sharing sequence
similarity to the smaller homologs such as SarA, SarR, and
SarT (Fig. 1). SarU has good homology with the MarR protein
of B. subtilis. The MarR proteins have been implicated in the
negative regulation of multiple antibiotic resistances in gram-
negative species (1). In particular, the expression of marAB,
the genes encoding the antibiotic efflux pump itself, is con-
trolled by the MarR repressor. A large number of compounds
induce the transcription of the marAB operon, presumably by
binding to MarR and thus preventing the binding of MarR to
the marAB promoter (1).
Within the S. aureus genome, a family of proteins homolo-
gous to SarA can now be identified. We called this group of
proteins the SarA protein family. Included in this family are
SarA, -R, -S, -T, and -U; we are in the midst of characterizing
other mutants within this protein family, including SarV (pro-
tein GI 13702067), SarX (protein GI 13700559), SarZ (protein
GI 13702335), and SarY (protein GI 13702097)(unpublished
data). To understand the mechanism of gene regulation in this
protein family, we recently determined the crystal structure of
SarR, a member of the SarA protein family (24). SarR is a
dimeric structure comprising five -helices, three -strands,
and several flexible loops (12-134-23-5). The SarR
structure can also be envisioned as a three-domain structure,
with a central helical core and two winged helix motifs. A short
turn between 3 and 4 constitutes a typical helix-turn-helix
motif (HTH) within each of the winged helix motifs. Deletion
analysis indicated that the HTH motif is essential to the func-
tion of SarA, the prototypic member of the SarA protein fam-
ily (7). In examining the amino acid sequence alignment (Fig.
1), the HTH region corresponds to residues 53 to 76 in the first
half and to residues 178 to 201 in the second half of the SarU
molecule. In the SarR dimeric structure, this region has been
modeled to be the DNA binding domain that maintains con-
tact with the major groove of DNA (24). Interestingly, many
basic residues (Lys54, Lys63, and Arg69 in SarU1 and Lys179
and Arg194 in SarU2) within this region are conserved within
the SarA protein family. Besides the HTH motif, the SarR
structure also predicts the beta hairpin loop (2-3) corre-
sponding to residues 81 to 97 in the first half and residues 206
to 212 in the second half to be another DNA-binding domain.
In particular, the basic residues Lys82 (residue 207), Arg84
(residue 209), Arg90 (residue 215), and acidic residues Asp88
(residue 213) and Glu89 (residue 214) of SarU within the
putative beta hairpin loop are absolutely conserved. These
data are consistent with the notion that the DNA-binding
domains might be highly conserved within this protein family.
The structure of MarR in E. coli has recently been described;
interestingly, MarR is also a dimeric structure with two winged
helix motifs (1).
Despite sequence similarity among members of the SarA
family, each member is also unique in its own function. This
FIG. 6. Northern blots of sarA, spa, and coa transcripts in the wild
type, sarU mutant, trans-complemented strains, sarA, agr, and sarT
mutants. A total of 10 g of RNA was applied to each lane. RNAs
extracted from the wild type (RN6390), various mutants, and comple-
mented strains are from the exponential (OD650, 0.7) and postexpo-
nential (OD650, 1.7) phases. (A) The blot was probed with a 400-bp
fragment containing the sarA open reading frame. The transcripts are
the larger sarA P2 (1.2 kb), sarA P3 (0.8 kb), and the smaller sarA P1
(0.5 kb) transcripts, respectively (4). (B and C) The blot was hybridized
with a 1.4-kb DNA fragment containing the spa gene (B) and a labeled
4.5-kb coa fragment of S. aureus as a probe (C).
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view is supported by the lesser degree of conservation within
the activation domain among family members, thus accounting
for diverse functions of the family members (24). For example,
SarS activates the synthesis of protein A, while SarT represses
the expression of -hemolysin (11, 36). Northern and tran-
scriptional analyses revealed that sarU likely activates agr, as
reflected by lower RNAII and RNAIII expression in a sarU
mutant than in the parental strain. Additionally, the expression
of sarU was also enhanced during the postexponential phase in
the sarT mutant, corresponding to a period when agr activation
is expected to be highest. This effect on agr is independent of
sarA, since the expression of SarA, the sarA regulatory mole-
cule, was not significantly altered in the sarU mutant compared
to that in the parental strain. We also confirmed that the
transcription of hla, a target gene of agr, was diminished in a
sarU mutant, in concordance with the decreased agr transcrip-
tion in the sarU mutant relative to that in the parental strain.
Moreover, the expression of one of the cell wall-associated
proteins (i.e., coagulase) controlled by agr was also increased in
the sarU mutant relative to the parental strain. However, the
effect of the sarU mutation on protein A expression is more
variable, with slightly lower expression in the sarU mutant than
in the parental strain, contrary to what one would expect from
reduced agr expression in a sarU mutant. This finding suggests
that besides its effect on agr and the ensuing target genes, sarU
may also regulate target genes via an agr-independent mecha-
nism, possibly like SarA-dependent regulation of virulence
genes (12).
In prior studies, we have made the observation that a mu-
tation in sarT has led to an increase in agr RNAIII expression
compared to that in the parental strain. Paradoxically, sarT
expression is also elevated in an agr mutant (36). Thus, the
identification of sarU, a gene repressed by sarT, has provided
the plausible link for a putative pathway whereby a feedback
loop on agr amplification can be discerned (Fig. 7). In this
scheme, activation of agr would repress sarT, leading to a
moderate increase in sarU transcription, presumably occurring
as a result of decreased SarT binding to the sarU promoter.
Secondary activation of sarU would promote transcription of
RNAII and RNAIII promoters of agr, leading to a further
increase in agr transcription. This model also predicts sarU
promoter activity to be lower in the agr mutant than in the
parent (Fig. 7). Given the constraint that the sarU promoter
was not highly active in the parent strain, we have consistently
found that the fluorescence attributable to the sarU promoter
was lower in the agr mutant than in the parent (Fig. 4B).
Viewed in this context, activation of agr via the sarT-sarU
pathway may represent an alternative mechanism to the pri-
mary quorum-sensing mechanism mediated by the cyclic auto-
inducing peptide (AIP). Although the RNAIII promoter can-
not be activated in an agr mutant in vitro, Xiong et al. have
found in a recent study that the RNAIII promoter can be
activated at a significant level in an agr mutant in a rabbit
endocarditis model (38). Whether the sarT-sarU activation
mechanism is deployed in vivo in response to host signals in the
absence of agr is not known. Nevertheless, the identification of
the sarT-sarU pathway has provided a plausible mechanism to
explain agr activation in vivo.
The sarU and sarT genes are divergently transcribed and are
separated by a 323-bp intergenic sequence between the two
FIG. 7. A model of the agr-sarT-sarU pathway for regulating the expression of virulence genes in S. aureus. SarA is synthesized during the
exponential phase based on differential activation of three sarA promoters (sarA P2, P3, and P1). SarR and SigB can down-regulate SarA
expression, and other factors may up-regulate it. The basal level of RNAII expression, in part in response to SarA, would lead to synthesis of the
AIP. Upon bacterial accumulation, the AIP would activate RNAIII transcription via a quorum-sensing mechanism. Besides the quorum-sensing
pathway, we also propose that RNAIII activation would lead to repression of SarT. SarT repression would result in elevated sarU and decreased
sarS expression; Rot protein acts as a repressor for hla expression (27). As SarU is an activator of RNAIII synthesis, this would provide a secondary
amplification of the original agr signal. Accordingly, this model predicts a reduction in RNAIII promoter activity in a sarU mutant as well as
decreased sarU promoter activity in an agr mutant compared to activities in the parental strain.
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coding regions. Transcriptional analysis indicated that sarU
expression is repressed by the sarT gene product and not vice
versa. Mapping of the transcriptional start site indicated that
the start site is located 90 bp upstream of the initiation codon
of the sarU gene, with typical A-dependent 10 and 35
promoter boxes. In gel shift studies, we found that purified
SarT can bind to the sarU promoter region with fairly high
affinity (Kd, 102.5 pM). As multiple protein-DNA complexes
are discerned, we speculate that multiple SarT dimers may
interact with each other to bind to the sarU promoter region.
This is based on our modeling data showing that three SarA
dimers may bind to a single 135-bp agr promoter fragment
(unpublished data). Nevertheless, we cannot exclude the pos-
sibility that a single dimer may bind to multiple sites on a
148-bp sarU promoter fragment.
Given that SarT is a repressor of sarU promoter activity, we
speculated that sarU is primarily transcribed in the absence of
SarT. Whether other factors are involved in augmenting sarU
transcription in a sarT mutant is not defined in this study. It is
curious that two hybridizing bands reacted with a sarU probe
that encompassed only the coding region in the sarT mutant.
Complementation of the sarU mutant with a 1.5-kb fragment
encompassing both the sarU gene and an 392-bp upstream
sequence restored only the smaller hybridizing band of 1,200
nt, presumably representing the monocistronic form of the
sarU RNA message. Complementation with a 2.3-kb fragment
containing 392-bp upstream and 1,158-bp downstream se-
quences of sarU plus the sarU coding region did not restore the
larger, 1,400-nt transcript (data not shown). Thus, the origin
of the larger hybridizing band remains unclear. The gene im-
mediately downstream of sarU encodes a 288-residue polypep-
tide, representing UTP-glucose-1-phosphate uridyltransferase
(gtaB). The gtaB gene is transcribed divergently from the
cDNA strand, with the stop codons of both genes being sepa-
rated by 210 bp. Northern hybridization with a 2.15-kb DNA
probe containing open reading frames of sarU and gtaB yielded
an additional 1,000-nt transcript (data not shown) distinct
from the 1.2-kb sarU RNA message. These data suggested
that the gtaB gene is likely to be controlled from its own
promoter and that the larger, 1,400-nt transcript that hybrid-
ized with the sarU probe is not part of the gtaB RNA message.
Upstream of sarT-sarU is a gene that encodes a hypothetical
protein (SA2285) homologous to these proteins with the
serine-aspartic acid repeats (e.g., clumping factors A and B),
and this gene is transcribed in the same orientation as sarT.
Given the size of the transcript (1,400 nt), this gene is un-
likely to be part of that message. Collectively, these data sug-
gested that the larger, 1,400-nt transcript might be a cross-
hybridizing band present in a sarT mutant. However, we did
not entirely rule out the possibility that a cryptic promoter may
originate upstream of sarU and that it is transcribed in opposite
orientation to sarT or other genes. Clearly, the molecular ar-
chitecture of the sarT-sarU loci needs to be further defined
before we can clearly assign the origin of the larger transcript.
In sum, the sarU gene product participates in the activation
of agr and some of its target genes (e.g., hla and coa). Addi-
tionally, sarU may also regulate target genes via an agr-inde-
pendent pathway. To further define the exact function of the
sarU gene product, we are in the process of constructing a
double knockout of sarU and sarT; the combination of a sarU
knockout together with mutations in sarA, sarR, sarS, agr, and
other regulatory genes may provide a clearer understanding of
the mechanism of virulence gene activation by SarU and other
members of the SarA protein family.
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